Sheffield Hallam University’s £900,000 Wellbeing Accelerator programme has welcomed its first international business.
Selfit Medical, an Israeli digital therapy start-up focussed on solutions to help ageing populations, has joined the programme based at Sheffield’s Advanced Wellbeing Research Centre (AWRC).
The start-up has developed a ‘robot therapist’ for people with brain and heart disorders. It guides individuals through a personalised physical therapy plan by projecting movement directions and combining audio prompts with the capacity to film and review.
Selfit’s patented system can help to alleviate issues associated with ageing and illness prevention, and managing other disorders – such as stroke, Parkinson’s disease, heart disease and cognitive impairment.
The Wellbeing Accelerator operates out of Sheffield Hallam’s new £14 million wellbeing research centre, with start-ups on the programme gaining access to world-class research and development to allow for rapid prototyping, precision engineering, laboratories for product testing, support networks and a clinical research centre.
The programme works with start-ups, SMEs, founders and agencies to accelerate the development of health and wellbeing technologies and applications. These innovations have become increasingly important this year as people adapt their lifestyles to the social restrictions triggered by the coronavirus pandemic.
Simon Butler, Head of the AWRC Wellbeing Accelerator, said: “We are delighted to accept Selfit Medical Ltd as the first international startup recruited on to the programme.
“Its technology is really innovative and very timely with the issues of an ageing population, and rising levels of conditions such as stroke and Parkinson’s meaning novel solutions are required. We look forward to supporting the business to reach its goals.”
Shahar Figelman, CEO of Selfit Medical, said: “We’ve been trying for some time to enter the UK healthcare and wellness markets so joining the AWRC Wellbeing Accelerator is a great opportunity for us.
“We’re excited to get access to leading scientists and clinicians via the programme and look forward to learning how to bring our technology to market in the UK.”